VERA THERAPEUTICS INC. - CLASS A COMMON STOCK

Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

27 فبراير 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock

06 فبراير 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

01 فبراير 2023 21:51:59 بحسب Nasdaq GlobeNewswire

Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock

01 فبراير 2023 16:01:00 بحسب Nasdaq GlobeNewswire

Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria

30 يناير 2023 06:00:00 بحسب Nasdaq GlobeNewswire

Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)

25 يناير 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

03 يناير 2023 16:01:00 بحسب Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

20 ديسمبر 2022 16:05:00 بحسب Nasdaq GlobeNewswire

Vera Therapeutics to Present at Upcoming Investor Conferences

22 نوفمبر 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP

17 نوفمبر 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

09 نوفمبر 2022 07:30:01 بحسب Nasdaq GlobeNewswire

Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidney Week 2022 Annual Meeting

05 نوفمبر 2022 16:50:00 بحسب Nasdaq GlobeNewswire

Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2022 Annual Meeting

17 أكتوبر 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Vera Therapeutics to Present at Upcoming Conferences in September 2022

07 سبتمبر 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

10 أغسطس 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

04 أغسطس 2022 07:30:01 بحسب Nasdaq GlobeNewswire

Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

06 يوليو 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Vera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients

04 يونيو 2022 14:30:00 بحسب Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

02 يونيو 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress

20 مايو 2022 16:05:00 بحسب Nasdaq GlobeNewswire